Testing Nivolumab and Ipilimumab Immunotherapy With or Without the Targeted Drug Cabozantinib in Recurrent, Metastatic, or Incurable Nasopharyngeal Cancer (clinicaltrials.gov) - Oct 22, 2026 - P2 | N=50 | Suspended | Sponsor: National Cancer Institute (NCI) | Trial completion date: Jun 2028 ➔ Dec 2028 | Trial primary completion date: Jun 2028 ➔ Dec 2028
Trial completion date • Trial primary completion date • Head and Neck Cancer • Nasopharyngeal Carcinoma • Oncology • Solid Tumor • PD-L1
|